# NextGen - Clinical Implication of Next Generation Sequencing

> **NCT05206500** · PHASE4 · RECRUITING · sponsor: **Wake Forest University Health Sciences** · enrollment: 100 (estimated)

## Conditions studied

- Urinary Tract Infections

## Interventions

- **DRUG:** Antibiotic
- **DEVICE:** Next Gen

## Key facts

- **NCT ID:** NCT05206500
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-17
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05206500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05206500, "NextGen - Clinical Implication of Next Generation Sequencing". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05206500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*